Tyrosine kinase inhibitors, such as gefitinib (Iressa ™, ZD1839), block the EGFR. As a result, there is inhibition of cellular proliferation, promotion of apoptosis, and inhibition of anti ...

"Our collaboration with Qilu marks a significant milestone in Minghui's commitment to advancing innovative cancer therapies," said Dr. Guoqing Cao, CEO of Minghui. "MHB088C has demonstrated robust ...

Mok and colleagues hypothesized that first-line therapy with the EGFR inhibitor gefitinib would be at least as efficacious as carboplatin–paclitaxel chemotherapy in former smokers and light ...

Minghui Pharmaceutical (Minghui), a late-stage clinical biopharmaceutical company, announced an exclusive licensing and collaboration agreement with Qilu Pharmaceutical (Qilu) for the development, ...

The authors conclude that EGFR copy number is a potential biomarker that could identify the patients with NSCLC who are most likely to benefit from gefitinib treatment.

SHANGHAI, May 9, 2025 /PRNewswire/ -- Minghui Pharmaceutical ("Minghui"), a late-stage clinical biopharmaceutical company, today announced an exclusive licensing and collaboration agreement with Qilu ...